COMPASS Pathways (CMPS) Is Up 7.1% After FDA Priority Status For COMP360 Psilocybin Therapy

• In April 2026, COMPASS Pathways reported that the FDA granted its COMP360 psilocybin therapy for treatment-resistant depression both rolling NDA review and selection for the Commissioner's National Priority Voucher program, providing enhanced agency engagement and a potentially shorter review window while maintaining safety and efficacy standards.
• The company also entered a collaboration with Osmind to study how independent psychiatry practices could deliver psychedelic treatments at scale, highlighting COMPASS Pathways’ focus on real-world implementation alongside late-stage clinical and regulatory progress.
• We’ll now examine how FDA rolling review for COMP360 and its National Priority Voucher status may reshape COMPASS Pathways’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

COMPASS Pathways Investment Narrative Recap

To own COMPASS Pathways, you need to believe COMP360 can convert its positive Phase 3 data and regulatory progress into an approved, scalable treatment for treatment resistant depression. The key near term catalyst is now the timing and outcome of the rolling NDA review. The biggest risk remains execution around approval and launch, especially given ongoing losses and funding needs. The new FDA rolling review and National Priority Voucher meaningfully sharpen the focus on that regulatory milestone.

The recent collaboration with Osmind feels particularly relevant here because it connects COMP360’s regulatory momentum with the practical question of how clinics could deliver psychedelic therapy at scale. While the FDA news centers the approval path, work with Osmind’s network of more than 1,000 interventional psychiatry practices touches the implementation risk that sits just behind approval in the catalyst stack.

Yet behind the faster FDA timetable, investors should be aware that...

Read the full narrative on COMPASS Pathways (it's free!)

COMPASS Pathways' narrative projects $193.1 million revenue and $24.2 million earnings by 2029. This requires earnings to improve by about $261.5 million from -$237.3 million today.

Uncover how COMPASS Pathways' forecasts yield a $21.92 fair value, a 130% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were only expecting around US$59,500,000 of revenue and US$6,500,000 of earnings by 2029, which reflects a much more cautious view on how clinic capacity, labeling and reimbursement might evolve compared with the upside many investors see after the FDA’s recent decision.

Explore 5 other fair value estimates on COMPASS Pathways - why the stock might be a potential multi-bagger!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your COMPASS Pathways research is our analysis highlighting 1 key reward and 5 important warning signs that could impact your investment decision.
• Our free COMPASS Pathways research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate COMPASS Pathways' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
• Find 48 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com